AstraZeneca: highlights potential of HVP cells
(CercleFinance.com) - AstraZeneca announces that an experimental study has shown that human ventricular progenitor cells (HVP) are capable of promoting the regeneration of healthy heart tissue after a heart attack, improving the heart function and reducing scar tissue.
Published in Nature Cell Biology, the research was conducted by AstraZeneca scientists in collaboration with the Technical University of Munich (TUM), TUM University Hospital Klinikum rechts der Isar, Karolinska Institutet and Procella Therapeutics.
The results showed a significant reduction in infarct volume of 7.0 ± 1.3% in the HVP-treated arm compared to 2.5 ± 1.6% in the untreated arm.
The share is up 2% on this news this morning.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Published in Nature Cell Biology, the research was conducted by AstraZeneca scientists in collaboration with the Technical University of Munich (TUM), TUM University Hospital Klinikum rechts der Isar, Karolinska Institutet and Procella Therapeutics.
The results showed a significant reduction in infarct volume of 7.0 ± 1.3% in the HVP-treated arm compared to 2.5 ± 1.6% in the untreated arm.
The share is up 2% on this news this morning.
Copyright (c) 2022 CercleFinance.com. All rights reserved.